IsoRay's Cesium-131 Cancer Treatment Products and Methods

RICHLAND, WA--(Marketwired - Sep 9, 2014) - IsoRay Inc. ( NYSE MKT : ISR ) ( www.isoray.com ), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 56 ^th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place September 14-17, 2014 in San Francisco, California at the Moscone Center, where papers, a panel discussion and dinner presentations are scheduled to be presented on results achieved using IsoRay's products.

According to IsoRay CEO Dwight Babcock, "With the recently published and peer reviewed results for gynecologic and metastatic brain cancer, several leading medical centers are now applying for Cesium-131 licenses which will permit them to perform procedures that have been reported in the medical journals. Cesium-131's success in treating recurrent cancers that have not responded to other treatments continues to get the attention of physicians who need new treatment options. The medical community is beginning to acknowledge the ability of IsoRay's Cesium-131 (Cs-131) seeds, seed sutured mesh and GliaSite ^® system for the treatment of a wide array of cancers throughout the body. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. We are extremely excited that published studies, posters and abstracts continue to be released showing positive results realized in treating metastasized brain cancers, gynecological cancers, lung cancer and prostate cancer using Cs-131 or GliaSite ^® . Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution."

IsoRay's hosted dinners and presentations at ASTRO are as follows:

1. Saturday, Dr Jonathan Feddock, MD, Cesium-131 Brachytherapy in Patients with Primary and Recurrent GYN Malignancies 2. Sunday, Dr. Brian J. Moran, MD, Cesium-131 Focal Prostate Brachytherapy 3. Monday, Dr. Bradley R. Prestidge, MD, Cesium-131 Prostate "Real Time" Stranded Technique

IsoRay is very pleased to have such industry leaders discuss the success, methods and new approaches being implemented in brachytherapy.

IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSite ^® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years.  Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers. 

About IsoRay  IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.  Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com . Join us on Facebook/Isoray.  Follow us on Twitter @Isoray .

Safe Harbor Statement Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSite ^® or Cesium-131 will increase or continue, whether additional medical institutions will seek, obtain and maintain required licenses to perform procedures with Cesium-131, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, patient results achieved with our products, successful completion of future research and development activities, our ability to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.